Suvorexant: First global approval

Drugs

Volumn 74, Issue 15, 2014, Pages 1817-1822

  Yang, Lily P H ^a  

^a Springer Mairangi Bay Auckland ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPRENAVIR; APREPITANT; ATAZANAVIR; BOCEPREVIR; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; CONIVAPTAN; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FOSAMPRENAVIR; IMATINIB; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; OREXIN A; OREXIN B; OREXIN RECEPTOR; PHENYTOIN; PLACEBO; POSACONAZOLE; RIFAMPICIN; SUVOREXANT; TELAPREVIR; TELITHROMYCIN; VERAPAMIL; AZEPINES; OREXIN RECEPTORS; TRIAZOLES;

ABNORMAL DREAMING; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CIRCADIAN RHYTHM; COUGHING; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GRAPEFRUIT JUICE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; LATERAL HYPOTHALAMUS; NERVE CELL; PARASOMNIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SLEEP; SOMNOLENCE; SUICIDAL IDEATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; WAKEFULNESS; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; HUMANS; SLEEP INITIATION AND MAINTENANCE DISORDERS;

AZEPINES; DRUG APPROVAL; HUMANS; OREXIN RECEPTORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRIAZOLES;

EID: 84910126991     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0294-5     Document Type: Article

References (22)

1. Buyssee DJ. Insomnia. JAMA. 2013;309(7):706.
2. Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status. CNS Drugs. 2013;27(2):83-90.
3. US Food and Drug Administration. FDA approves new type of sleep drug, Belsomra [media release]. 13 August 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm.
4. ® (suvorexant) US prescribing information. 2014. http://www.merck.com/product/usa/pi-circulars/b/belsomra/belsomra-pi.pdf. Accessed 18 Aug 2014.
5. Merck & Co. Merck receives Complete Response Letter for suvorexant, Merck's investigational medicine for insomnia [media release]. 1 July 2013. http://www.merck.com.
6. US Federal Register. Schedules of controlled substances: placement of suvorexant into schedule IV. 2014. https://www.federalregister.gov/articles/2014/08/28/2014-20515/schedules-of-controlled-substances-placement-of-suvorexant-into-schedule-iv?utm-campaign=subscription+mailing+list&utm-medium=email&utm-source=federalregister.gov. Accessed 10 Sep 2014.
7. Connor K, Budd K, Snavely D, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1) [abstract no. O324]. J Sleep Res. 2012;21(Suppl 1):97.
8. Ivgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2) [abstract no. P988]. J Sleep Res. 2012;21(Suppl 1):351-2.
9. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461-71.
10. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265-74.
11. Merck & Co. Merck announces full-year and fourth-quarter 2012 financial results. 2012.
12. Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant: a novel dual orexin receptor antagonist. J Neurogenet. 2011;25(1-2):52-61.
13. US Food and Drug Administration. Suvorexant Advisory Committee Meeting briefing document. 2013. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm352970.pdf. Accessed 9 Sep 2014.
14. Sun H, Kennedy D, Lewis N, et al. The single dose pharmacokinetic (PK) and pharmacodynamic (PD) profiles of suvorexant (MK-4305), a dual orexin receptor antagonist, in healthy male subjects [abstract no. PI-59]. Clin Pharmacol Ther. 2012;91(Suppl 1):S29.
15. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259-67.
16. Sun H, Yee KL, Khalilieh S, et al. Phase 1 safety, pharmacokinetics, and pharmacodynamics of the orexin receptor antagonist suvorexant administered with alcohol or paroxetine [abstract no. 0650]. Sleep. 2013;36(Suppl):A224.
17. Herring WJ, Ivgy-May N, Connor KM, et al. Effect of suvorexant, an orexin receptor antagonist, on patient-reported outcomes in patients with primary insomnia: integrated results from two phase-3 trials [abstract no. 0648]. Sleep. 2013;36(Suppl):A223.
18. Hisada S, Kikuchi M, Takahashi K, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase III study (P028) [abstract no. 0649]. Sleep. 2013;36(Suppl):A224.
19. Connor KM, Matzura-Wolfe D, Zhang Y, et al. Safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: integrated phase 3 results [abstract no. 0647]. Sleep. 2013;36(Suppl):A223.
20. Vermeeren A, Vuurman E, Van Oers A, et al. Effects of suvorexant, an orexin receptor antagonist, on next day driving performance in healthy volunteers [abstract no. W11]. In: 51st Annual Meeting of the American College of Neuropsychopharmacology; 2-6 Dec 2012; Hollywood (FL).
21. Uemura N, McCrea J, Sun H, et al. Effects of supratherapeutic and therapeutic doses of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects [abstract no. 0645]. Sleep. 2013;36(Suppl):A222.
22. Troyer M, Uemura N, McCrea J, et al. Respiratory safety of the orexin receptor antagonist suvorexant during sleep in patients with compromised respiratory function and in healthy subjects [abstract no. P5.293]. Neurology. 2014;82(10 Suppl 1).